Learning Objectives: -Develop an understanding of the scientific rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of lymphoma. -Appreciate long-term efficacy and safety data with FDA-approved CAR T-cell therapies directed at CD19 in multiply relapsed diffuse large B-cell lymphoma (DLBCL). -Identify patients with DLBCL relapsing on first-line therapy for whom treatment with CAR T-cell therapy would be appropriate. -Evaluate published research findings to determine the current clinical role of CAR T-cell therapy in patients with other B-cell lymphomas including mantle cell lymphoma and follicular lymphoma. -Appreciate available data documenting the activity of CAR T-cell therapy in patients with relapsed/refractory chronic lymphocytic leukemia in preparation for the potential clinical availability of this therapeutic strategy. -Implement strategies to educate patients eligible for treatment with CD19-directed CAR T-cell therapy about the potential for short- and long-term complications.
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://www.researchtopractice.com
- Start Date: 2024-10-04 05:00:00
- End Date: 2024-10-04 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- MOC Credit Details: ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Bristol Myers Squibb - Amount: 46750.0 - Is Kind Support: False Source: Novartis - Amount: 7650.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology